The Metastatic Castration-resistant Prostate Cancer market growth is driven by factors like increase in the prevalence of Metastatic Castration-resistant Prostate Cancer, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Metastatic Castration-resistant Prostate Cancer market report also offers comprehensive insights into the Metastatic Castration-resistant Prostate Cancer market size, share, Metastatic Castration-resistant Prostate Cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Metastatic Castration-resistant Prostate Cancer market size growth forward.
Some of the key highlights from the Metastatic Castration-resistant Prostate Cancer Market Insights Report:
Strategise your business goals by understanding market dynamics @ Metastatic Castration-resistant Prostate Cancer Market Landscape
Metastatic Castration-resistant Prostate Cancer Overview
Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years. CRPC was previously named “hormone-refractory prostate cancer” and “androgen-independent prostate cancer”. However, because castration treatments including ADT were ineffective, these cancers still showed reliance upon hormones for androgen receptor (AR) activation.
Do you know the treatment paradigms for different countries? Download our Metastatic Castration-resistant Prostate Cancer Market Sample Report
Recent Breakthroughs in the Metastatic Castration-resistant Prostate Market:
FDA Approves Olaparib Plus Abiraterone and Prednisone or Prednisolone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: On May 31, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) in combination with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.
Metastatic Castration-resistant Prostate Cancer Epidemiology Segmentation
DelveInsight’s Metastatic Castration-resistant Prostate Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Metastatic Castration-resistant Prostate Cancer historical patient pools and forecasted Metastatic Castration-resistant Prostate Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Metastatic Castration-resistant Prostate Cancer Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Visit for more @ Metastatic Castration-resistant Prostate Cancer Epidemiological Insights
Metastatic Castration-resistant Prostate Cancer Treatment Market
The Metastatic Castration-resistant Prostate Cancer market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Metastatic Castration-resistant Prostate Cancer market trends by analyzing the impact of current Metastatic Castration-resistant Prostate Cancer therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Metastatic Castration-resistant Prostate Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Metastatic Castration-resistant Prostate Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Metastatic Castration-resistant Prostate Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.
Metastatic Castration-resistant Prostate Cancer Therapy Assessment
SRF617: Surface Oncology
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.
Rucaparib: Clovis Oncology
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.
HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
Metastatic Castration-resistant Prostate Cancer Key Companies
For more information, visit Metastatic Castration-resistant Prostate Cancer Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Metastatic Castration-resistant Prostate Cancer Market Report:
Key Questions Answered in the Metastatic Castration-resistant Prostate Cancer Market Report 2032:
Table of Contents:
1 Metastatic Castration-resistant Prostate Cancer Market Key Comprehensive Insights
2 Metastatic Castration-resistant Prostate Cancer Market Report Introduction
3 Competitive Intelligence Analysis for Metastatic Castration-resistant Prostate Cancer
4 Metastatic Castration-resistant Prostate Cancer Market Analysis Overview at a Glance
5 Executive Summary of Metastatic Castration-resistant Prostate Cancer
6 Metastatic Castration-resistant Prostate Cancer Epidemiology and Market Methodology
7 Metastatic Castration-resistant Prostate Cancer Epidemiology and Patient Population
8 Metastatic Castration-resistant Prostate Cancer Patient Journey
9 Metastatic Castration-resistant Prostate Cancer Treatment Algorithm, Metastatic Castration-resistant Prostate Cancer Current Treatment, and Medical Practices
10 Key Endpoints in Metastatic Castration-resistant Prostate Cancer Clinical Trials
11 Metastatic Castration-resistant Prostate Cancer Marketed Therapies
12 Metastatic Castration-resistant Prostate Cancer Emerging Therapies
13 Metastatic Castration-resistant Prostate Cancer: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Metastatic Castration-resistant Prostate Cancer
16 Metastatic Castration-resistant Prostate Cancer Market Key Opinion Leaders Reviews
18 Metastatic Castration-resistant Prostate Cancer Market Drivers
19 Metastatic Castration-resistant Prostate Cancer Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Metastatic Castration-resistant Prostate Cancer Epidemiology 2032
DelveInsight’s “Metastatic Castration-resistant Prostate Cancer – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Metastatic Castration-resistant Prostate Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Metastatic Castration-resistant Prostate Cancer Pipeline 2023
“Metastatic Castration-resistant Prostate Cancer Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Metastatic Castration-resistant Prostate Cancer market. A detailed picture of the Metastatic Castration-resistant Prostate Cancer pipeline landscape is provided, which includes the disease overview and Metastatic Castration-resistant Prostate Cancer treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +91-9650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
